Terms of Reference:

• This committee has been seconded by the Canadian Rheumatology Association (CRA) to work with nation organizations such as insurance companies and the panCanadian Pharmaceutical Alliance (pCPA)
• Identify and represent the needs of ORA and CRA members with respect to drug access through payers other than the provincial governments
• Meet on an as-needed basis with organizations such as the Canadian Life and Health Insurance Association ( CLHIA) and other groups as deemed appropriate discuss drug access development and implementation of projects that advance the interests of ORA and CRA members
• Actively promote the creation of truly panCanadian drug access for patients with rheumatic diseases by created panCanadian criteria for drug access regardless of payer